Calidi Biotherapeutics (NYSE:CLDI – Get Free Report) and Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Institutional & Insider Ownership
12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Calidi Biotherapeutics and Cullinan Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Calidi Biotherapeutics | $50,000.00 | 535.55 | -$29.22 million | N/A | N/A |
| Cullinan Therapeutics | $18.94 million | 41.35 | -$153.16 million | ($2.84) | -4.74 |
Profitability
This table compares Calidi Biotherapeutics and Cullinan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Calidi Biotherapeutics | N/A | N/A | -344.45% |
| Cullinan Therapeutics | N/A | -26.54% | -25.32% |
Risk & Volatility
Calidi Biotherapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Calidi Biotherapeutics and Cullinan Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Calidi Biotherapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Cullinan Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Calidi Biotherapeutics presently has a consensus price target of $16.67, suggesting a potential upside of 591.56%. Cullinan Therapeutics has a consensus price target of $31.67, suggesting a potential upside of 135.44%. Given Calidi Biotherapeutics’ higher probable upside, equities research analysts clearly believe Calidi Biotherapeutics is more favorable than Cullinan Therapeutics.
Summary
Calidi Biotherapeutics beats Cullinan Therapeutics on 6 of the 10 factors compared between the two stocks.
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
